American Association for the Advancement of Science, Science Translational Medicine, 571(12), 2020
DOI: 10.1126/scitranslmed.aaz6667
Full text: Unavailable
A combination of metabolic reprogramming and T cell therapy via surface anchor-engineering results in improved efficacy of immunotherapy in solid tumors.